Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10012652 | 0.75 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL27653186 | 0.71 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28238934 | 0.71 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3065985 | 0.70 | GRIN2D (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3065982 | 0.70 | GRIN2D (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29139136 | 0.68 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3896373 | 0.67 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6517328 | 0.64 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3071615 | 0.63 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1539097 | 0.62 | GRIN2D (0.38) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601728-B2 | Bicyclic pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | GRIN2D 1259/4885GRIN3B 1210/4885GRIN1 979/4885 |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | GRIN2D 1517/4885GRIN3B 1484/4885GRIN1 1215/4885 |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | GRIN2D 1517/4885GRIN3B 1484/4885GRIN1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.